^
    2ms
    Self-Tumor Antigens in Solid Tumors Turned into Vaccines by α-gal Micelle Immunotherapy. (PubMed, Pharmaceutics)
    It is suggested that, in addition to converting treated metastases into an autologous TA vaccine, this treatment should be considered as a neoadjuvant therapy, administering α-gal micelles into primary tumors immediately following their detection. Such an immunotherapy will convert tumors into a personalized anti-TA vaccine for the period prior to their resection.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    alpha-gal glycolipids (AGI-134)
    11ms
    Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour (clinicaltrials.gov)
    P1/2, N=40, Completed, Agalimmune Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    alpha-gal glycolipids (AGI-134)
    almost5years
    AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models. (PubMed, Cancer Cell Int)
    Combinations of AGI-134 and anti-PD-1 antibody shows a synergistic benefit in protection from secondary tumor growth. We have identified AGI-134 as an immunotherapeutic drug candidate, which could be an excellent combination partner for anti-PD-1 therapy, by facilitating tumor antigen processing and increasing the repertoire of tumor-specific T cells prior to anti-PD-1 treatment.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    alpha-gal glycolipids (AGI-134)